Predictive Value of PREMM5, MMRpredict, and Universal Tumor Screening for Lynch Syndrome in Vietnam

• Background and Rationale Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide and the second leading cause of cancer-related deaths. Approximately 5-6% of CRC cases are associated with hereditary cancer syndromes, with Lynch Syndrome (LS) being the most common. LS results from germline mutations in the Mismatch Repair (MMR) genes (MLH1, MSH2, MSH6, PMS2, and EPCAM), which lead to microsatellite instability (MSI) and an increased risk of CRC, endometrial, and other extracolonic malignancies.

Despite its significance, LS remains underdiagnosed, particularly in Asian populations, due to the limitations of traditional screening criteria, such as Amsterdam II and the Revised Bethesda Guidelines, which have low sensitivity in identifying LS patients. In response, universal tumor-based screening using MSI testing and immunohistochemistry (IHC) for MMR protein loss has been proposed as an effective alternative. Additionally, prediction models such as PREMM5 and MMRpredict have been developed to estimate LS risk based on clinical and family history.

However, these models and tumor screening strategies have not been validated in the Vietnamese population. This study aims to evaluate and compare the predictive performance of different screening approaches for LS in Vietnamese CRC patients, thereby optimizing genetic testing selection and early diagnosis.

• Study Design and Setting

This is a cross-sectional study conducted at two major hospitals in Vietnam:

• University Medical Center at Ho Chi Minh City - GI Endoscopy Department
• Nguyen Tri Phuong Hospital - GI Endoscopy & Gastrointestinal Surgery Departments The study will enroll CRC patients aged 18-70 years who undergo colonoscopy with suspected tumors and are subsequently diagnosed with colorectal adenocarcinoma.
• Objectives

Primary Objective:

• To assess the predictive value of PREMM5, MMRpredict, and Universal Tumor Screening Strategy in detecting Lynch Syndrome in CRC patients.

Secondary Objectives:

• To determine the prevalence of Lynch Syndrome based on germline MMR gene mutation testing.
• To describe the clinical characteristics of Lynch Syndrome-Associated CRCs.
• To describe the the endoscopic and histopathological features of Lynch Syndrome-Associated CRCs
• To compare the diagnostic accuracy (AUC-ROC, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV)) of different screening models and criteria, including Amsterdam II, Revised Bethesda Guidelines, PREMM5, MMRpredict, and Universal Tumor Screening.
• Study Procedures Patient Enrollment & Sample Collection

Eligible patients will:

• Provide informed consent before participation.
• Complete a medical history questionnaire assessing:

• Family history of CRC and LS-related cancers.
• Personal history of CRC, endometrial, and other extracolonic malignancies.
• Clinical symptoms and lifestyle risk factors.
• Provide a 2 mL blood sample for germline genetic testing.
• Laboratory Analysis

• Histopathological Evaluation: Tumor biopsy samples will be fixed in formalin, sectioned, and stained for Hematoxylin-Eosin (H&E) evaluation.
• MMR Protein Expression: IHC will assess the loss of MLH1, MSH2, MSH6, and PMS2 expression.
• BRAF V600E Mutation & MLH1 Methylation: Tumors with MLH1/PMS2 loss will undergo further testing to determine sporadic vs. hereditary LS cases.
• Germline MMR Mutation Testing: All the blood samples will undergo Next-Generation Sequencing (NGS) to detect pathogenic germline MMR mutations.
• Biallelic Somatic Mutation Analysis: If no germline mutations are identified in case of MLH1/PMS2 expression loss and no BRAF V600E mutation and no MLH1 methylation, tumor tissue sequencing will determine biallelic somatic inactivation.
• Statistical Considerations Sample Size Calculation The sample size is calculated based on the estimated prevalence of LS at 2.9%, requiring at least 572 participants (including a 10% dropout rate) to achieve statistical power.
• Statistical Analysis

• Quantitative variables (e.g., age, tumor size) will be expressed as mean ± standard deviation or median with interquartile range.
• Categorical variables (e.g., IHC results, BRAF V600E mutation) will be reported as percentages.
• Diagnostic performance will be evaluated using Receiver Operating Characteristic (ROC) curves, sensitivity, specificity, PPV, and NPV.
• Comparison of screening models (Amsterdam II, Bethesda, PREMM5, MMRpredict, Universal Tumor Screening) will be based on their AUC-ROC values.
• Significance level: p < 0.05.
• Ethical Considerations This study adheres to Good Clinical Practice (GCP) and the Declaration of Helsinki. Ethical approval has been obtained from the Institutional Review Board (IRB), and all participants will provide written informed consent.

• Patient confidentiality will be ensured by de-identifying all study data.
• All data will be retained for at least three years post-study completion. Data Quality and Monitoring
• Standard Operating Procedures (SOPs): Guidelines will be followed for sample collection, DNA extraction, MSI/IHC testing, and genetic analysis.
• Plan for Missing Data: Cases with missing or inconsistent data will be reviewed, and statistical methods such as multiple imputation will be used if necessary.
• Registry Oversight & Compliance: The study will follow national biomedical research regulations and ensure compliance with international registry requirements (e.g., ClinicalTrials.gov).
• Study Duration and Expected Outcomes

• Study Duration: 24 months (March 2025 - March 2027).
• Expected Outcomes:

• Improved LS detection rates in Vietnamese CRC patients.
• Validation of prediction models (PREMM5, MMRpredict) in the Vietnamese population.
• Enhanced cost-effectiveness in LS screening and genetic testing selection.
• Contribution to national screening guidelines for hereditary cancer syndromes. By refining LS screening strategies, this study will support early cancer detection, preventive interventions, and genetic counseling in Vietnam.

Inclusion criteria

• Aged 18 to 70 years
• Provide informed consent to participate in the study
• Undergo colonoscopy with endoscopic findings suspicious for CRC
• Have biopsy-confirmed adenocarcinoma through colonoscopic biopsy

Exclusion criteria

• Active gastrointestinal bleeding
• Currently using anticoagulants or antiplatelet agents
• History of coagulation disorders or difficulty controlling bleeding
• Incomplete colonoscopy to the cecum (excluding cases of tumor-induced obstruction)